VISCHER advises GlycoVaxyn AG, a leader in the development of innovative vaccines, entering into research and development collaboration and license agreement with Janssen Phar-maceuticals (JPI), to develop a multi-valent bacterial vaccine on the basis of its unique, pro-prietary in vivo glycosylation platform. GlycoVaxyn will collaborate with JPI?s affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which JPI will be responsible for later-stage clinical studies and world-wide commercialization. GlycoVaxyn located in Schlieren near Zurich is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners. The VISCHER team is led by Matthias Staehelin (Corporate) with Christian Wyss.